Incyte Corp (NAS:INCY)
$ 69.91 0.07 (0.1%) Market Cap: 13.47 Bil Enterprise Value: 11.73 Bil PE Ratio: 499.36 PB Ratio: 4.25 GF Score: 89/100

Incyte Corp at JMP Securities Life Sciences Conference Transcript

Jun 18, 2020 / 07:00PM GMT
Release Date Price: $97.36 (+1.12%)
Reni John Benjamin
JMP Securities LLC, Research Division - MD & Equity Research Analyst

Excellent. Good afternoon, everyone, and welcome to the fireside chat with Incyte Corporation. It's my pleasure to introduce Hervé, Christiana and Peter from Incyte. As they know, and I've been telling our investors, we never know who is involved, who is listening in, whether they know Incyte or not, so I'd love to take, call it, 2 to 4 minutes, Hervé, if you can, just give us a good global sketch of what Incyte is about.

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Okay. Yes. No, thank you for the invitation. And I mean describing Incyte in 4 minutes is a little bit challenging. But basically, the whole idea behind Incyte is that discovering new products can translate into changes in the practice of medicine, obviously, and create a very fast-growing and diversified portfolio for the future in our case.

So we are a company that is heavily inclined into doing drug discovery and drug development. We have now received FDA

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot